Latest News
Category: News
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at Olivia Newton-John Cancer and Wellness Centre (Austin Health) on 20th August 2019, as part of the international ZIRCON (Zirconium Imaging in Renal Cancer Oncology)...
Read more
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6...
Read more
Telix Pharmaceuticals is pleased to announce Telix’s CEO, Dr. Christian Behrenbruch will present at the Jefferies Healthcare Conference at the Grand Hyatt Hotel in New York at 8:00 AM EDT...
Read more
Telix Pharmaceuticals Limited is pleased to provide its Annual Report...
Read more
Telix has just launched an information site on our illumet™ prostate cancer imaging product. The website provides an informative depository about how the product works and its potential in clinical...
Read more
Telix Pharmaceuticals Limited today announced a strategy update for the TLX591 (prostate therapy)...
Read more
Telix Pharmaceuticals Limited is pleased to provide a detailed Program Update January...
Read more
Telix Pharmaceuticals has today announced a clinical collaboration with Radboud University Medical...
Read more
News,
Telix is pleased to provide details of BioSpectrum Asia interview with Telix Japan President & COO Dr Shintaro Nishimura on the APAC oncology market & opportunities/challenges in the Japanese market...
Read more
News,
Telix Pharmaceuticals Limited is delighted to announce the appointment of Ms. Odile Jaume as President and Chief Operating Officer (COO) of Telix’s European...
Read more